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BLOCKING EXPRESSION OF INHIBITORY RECEPTOR NKG2A OVERCOMES TUMOR RESISTANCE TO NK CELLS
, and after infusion of NK cells activated ex vivo by cytokines (4, 6) . Clinical activity, however, remains difficult to predict, responses are often not durable, and therapeutic potential against tumors beyond AML is unclear (7, 8) .
NK cells have the inherent capacity to identify, and specifically eliminate, virallyinfected or transformed cells (7) (8) (9) . NK activating and inhibitory receptors, ligated to varying degrees by molecules expressed on candidate target cells, regulate these functions (8, 9) . The CD94/NK Group 2 member A (NKG2A) heterodimeric receptor is one of the most prominent NK inhibitory receptors (10) . It binds to a non-classical minimally polymorphic human leukocyte antigen (HLA) class I molecule (HLA-E), which presents peptides derived from leader peptide sequences of other HLA class I molecules, such as HLA-G (11) (12) (13) (14) (15) . Upon ligation by peptide-loaded HLA-E, NKG2A transduces inhibitory signaling through two inhibitory immunereceptor tyrosine-based inhibition motifs, thus suppressing NK cytokine secretion and cytotoxicity (16) (17) (18) .
Although HLA-E transcripts are ubiquitously expressed (19) , surface expression of HLA-E is often weak or undetectable in tumor cell lines (20) . During anti-tumor immune responses, however, interferon (IFN)secreted by immune cells upregulates HLA-E expression in tumor 4 cells (21) (22) (23) . Stabilized by peptide loading (24) , the HLA-E-peptide complex dampens initial NK cell responses by binding CD94/NKG2A. HLA-E is indeed overexpressed in several tumors (25) (26) (27) (28) (29) (30) (31) (32) (33) , and a correlation between higher HLA-E and poorer prognosis has been observed (25, 27) . Moreover, NKG2A+ NK cells are reportedly predominant in the tumor microenvironment. Thus, intratumoral NK cells in patients with non-small cell lung cancer have higher expression of NKG2A than those obtained from non-tumoral distant sites (34, 35) .
Likewise, NKG2A expression is higher in NK cells infiltrating breast cancer tumors than in those isolated from symmetric normal breast tissue (36) , and in peripheral blood NK cells of patients with AML compared to NK cells of age-matched controls (37) . Because of the strong evidence for the suppressive effect of NKG2A on NK cell activity, this immune checkpoint has been targeted with antibodies that block its interaction with HLA-E, currently in clinical development (38) (39) (40) (41) .
In this study, we first determined HLAE expression in approximately 10,000 tumor samples, and assessed its relation with that of KLRC1 (NKG2A) and KLRD1 (CD94). Then, we sought to develop NK cells that were impervious to the inhibitory effects of HLA-E. To this end, we designed constructs, named Protein Expression Blockers (PEBLs), that prevent the transport of NKG2A to the cell surface membrane of NK cells. Finally, we tested whether downregulation of NKG2A could overcome the HLA-E-mediated mechanism of tumor resistance to NK cell killing.
RESULTS
HLAE expression in tumor samples, relation with immune cell infiltration and
KLRC1/KLRD1 expression
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We performed an unbiased analysis of HLAE expression in human tumors using data from 10,375 tumor samples, representing 33 tumor types, made available by The Cancer Genome Atlas (TCGA) Research Network: http://cancergenome.nih.gov/. We found considerable inter-and intra-tumor heterogeneity in HLAE expression (Fig. 1A) . Tumor types with more than 100 samples whose median HLAE expression exceeded the median value (log10 transcripts per kilobase million of 3.92) included clear cell kidney cancer (KIRC), head and neck squamous cell carcinoma (HNSC), non small cell lung adenocarcinoma (LUAD), melanoma (SKCM), prostate adenocarcinoma (PRAD), gastric adenocarcinoma (STAD), colon adenocarcinoma (COAD), cervical cancers (CESC), squamous non small cell lung cancer (LUSC), and rectal adenocarcinoma (READ).
When all tumors were analyzed collectively, there was a direct relation between levels of HLAE expression and those of KLRC1 (NKG2A) (Pearson correlation coefficient r = 0.48) and KLRD1 (CD94) (r = 0.57), while there was no relation with the activating member of the NKG2 family KLRC2 (NKG2C) (r = 0.07) (Figs. 1B,C) . The correlation between HLAE and KLRC1 was particularly evident in some tumors, such as bladder urothelial carcinoma (BLCA), sarcoma (SARC), CESC, HNSC, and PRAD (Fig. 1D) .
We further assessed the correlation between HLAE and KLRC1 using Tumor IMmune Estimation Resource (TIMER; https://cistrome.shinyapps.io/timer/), which allows estimates of immune-cell infiltration (42) . Among tumors with more than 100 samples, the highest correlation values were observed in BLCA, thyroid carcinoma (THCA), thymoma (THYM), HNSC and breast cancer (BRCA); the lowest were in low grade glioma (LGG), glioblastoma multiforme (GBM), KIRC and pheochromocytoma/paraganglioma (PCPG) ( Table S1 ). Expression of HLAE correlated with that of genes encoding IFN, markers associated with cytolytic immune cells 6 (perforin, granzyme A), NK cells (NKG2D, NCR3, CD16) and T cells (CD3, CD8, CD4) (Fig.   S1 ). The correlations with KLRC1 were maintained after conditioning the analysis for tumor purity (Table S1 , Fig. S2 ), suggesting a relation between HLAE and KLRC1 regardless of the degree of immune cell infiltration. KLRC1 expression in tumor tissues was also strongly associated with that of genes encoding IFN, perforin and granzymes, as well as with genes expressed in NK and T cells (Fig. S3) .
Downregulation of NKG2A in NK cells
We reasoned that the anti-tumor capacity of NK cell infusions in an HLA-E-rich tumor microenvironment would increase if NK cells could bypass the HLA-E checkpoint. To this end, we designed PEBLs consisting of a single chain variable fragment (scFv) derived from the sequence of an anti-NKG2A monoclonal antibody (Z199) (17, 43) linked to 4 different endoplasmic reticulum (ER) retention domains ( Fig. 2A ). PEBL1 contains a (GGGGS)4AEKDEL domain; it binds the KDEL (lysine, aspartic acid, glutamic acid, leucine) peptide receptor, linked to the coat protein complex I (COPI) vesicular transport which mediates protein traffic between ER and Golgi (44, 45) . PEBLs 2-4 contain different peptides containing KKMP (lysine, lysine, methionine, proline) domains, together with CD8 hinge and transmembrane domains; these allow direct binding to COPI (45, 46) .
To test the capacity of PEBLs to downregulate NKG2A, we inserted the constructs into a murine stem cell virus (MSCV) retroviral vector containing green fluorescent protein (GFP), and use it to express the anti NKG2A PEBLs in the NKG2A + cell line NK92. NKG2A expression was essentially abrogated in all GFP+ NK92 cells (Fig. 2B ). PEBLs were not detectable on the cell surface, whereas a surface membrane-bound anti-NKG2A scFv used as a control was highly 7 expressed ( Fig. S4) , indicating that PEBLs were confined to the intracellular space.
To determine whether anti-NKG2A PEBLs could also downregulate NKG2A expression in primary human NK cells, we expanded peripheral blood NK cells (n=10 from 9 donors) by a 5-6 day stimulation with the K562-mb15-41BBL cell line (47, 48) . We then purified NKG2A+ NK cells by magnetic bead-positive selection, and transduced them with anti-NKG2A-PEBL2.
Percentage of NKG2A+ cells before purification was 69.8% ± 11.8%, and increased to 98.8% ± 1.6% after purification. Transduction of anti-NKG2A PEBL markedly reduced NKG2A. Among GFP+ cells, representing 49.1 % to 82.0% (median, 68.2%) of all NK cells, NKG2A+ cells were 7.5% ± 5.9%, while in cells transduced with a vector containing only GFP, NKG2A expression remained high (97.6% ± 3.2%; P <0.0001) (Fig. 2C,D) .
Cell markers, gene expression and functional features of NKG2A null
NK cells
Anti-NKG2A PEBL transduction resulted in downregulation of CD94 surface expression (Fig. 3A,B) . In the 7 donors tested, residual CD94+ cells represented 21.9%-45.1% (median, 37.8%) of NK cells transduced with PEBL versus 89.9%-99.7% (median, 96.8%) of NK cells transduced with GFP alone. After staining the cells with anti-NKG2A antibody, and testing for CD94 expression after cell permeabilization, we found that CD94 was expressed in PEBL cells at levels similar to those measured in control cells (Fig. S5) , suggesting that CD94 was synthesized normally in PEBL cells but less expressed on the cell membrane owing to the lack of NKG2A expression.
Anti-NKG2A PEBL transduction did not affect expression of other NK cell molecules, including CD56, CD16, CD69, CD57, CD335 (NKp46), CD336 (NKp44), CD337 (NKp30), CD158a, CD158b, CD158e, CD226 (DNAM-1), NKG2D and CD137 (4-1BB), granzyme A, 8 granzyme B and perforin (Fig. S6A) . Expression of CD159c (NKG2C) was also similar in PEBL-transduced and control NK cells (Fig. 3C) (Fig. 3D) . Nevertheless, PEBL-transduced NK cells could expand as well as control NK cells with interleukin-2 (IL-2) (Fig. 3E) . Likewise, the IL-2-dependent cell line NK92 continued to proliferate normally after downregulation of NKG2A (Fig. S6B ).
We applied RNA sequencing to examine the expression of 44 genes encoding NK activating and inhibitory receptors, cytokines and cytokine receptors, and cytolytic molecules.
There were no differences in mRNA expression for NKG2A, CD94, and NKG2C, and none of the other 41 genes was marked as a "discovery" after controlling for false discovery rate (Table   S2 ).
To further examine the functionality of NKG2A To test whether NKG2A downregulation released NK cells from HLA-E-mediated inhibition, we generated tumor cells with strong NKG2A binding potential. For this purpose, we transduced the ligand of NKG2A, i.e., HLA-E plus HLA-G signal peptide ("GpHLA-E") (49, 50) in tumor cell lines derived from AML (K562), osteosarcoma (U2OS) and Ewing's sarcoma (ES8 and EW8) (Fig. S7A ). These cell lines express a variable profile of inhibitory and activating NK ligands: the inhibitory HLA-Class I is absent or dim in K562 and ES8, but highly expressed in U2OS and EW8; the activating NKG2D ligands MICA/B and ULBP1-3 and the DNAM-1 ligands CD112 and CD155 are expressed in all 4 lines but at generally low levels in ES8 and EW8 (51) . Regardless, GpHLA-E expression markedly inhibited CD107a secretion by NKG2A+ NK cells, and NK cytotoxicity overall ( and NKG2C expression (Fig. 4B) . Importantly, NKG2A downregulation did not increase cytotoxicity against autologous activated CD4+ T cells (Fig. S8A ), an effect which NKG2A had been previously reported to suppress (52, 53) . Cytotoxicity against bone marrow-derived mesenchymal cells (54) also remained low, regardless of IFN stimulation (Fig. S8B) . Thus, gains in anti-tumor activity by NKG2A downregulation were not accompanied by increased toxicity against non-transformed cells.
Antibody binding to NKG2A may reduce its NK inhibitory activity (38, 39, 41, 55) . To compare the effect of anti-NKG2A PEBL to that of antibody interference with NKG2A, we preincubated NKG2A+ cells with either the anti-NKG2A antibody Z199, or an isotype-matched non-reactive antibody. We then tested their capacity to kill GpHLA-E-transduced K562, U2OS and ES8 cells. Although Z199 significantly improved the cytotoxicity of control NK cells against all 3 targets, the same NK cells transduced with anti-NKG2A PEBL were consistently more cytotoxic (Fig. 4C ).
To further test the gains in anti-tumor activity afforded by NKG2A downregulation, we performed long-term cytotoxicity assays at low (1:2-1:8) E:T ratios against GpHLA-E- 
NKG2A downregulation increases NK cell killing of tumor cells exposed to IFNand suppresses NKG2A upregulation by IL-12
The above experiments showed that downregulation of NKG2A dramatically reduced the inhibition exerted by transduced GpHLA-E. We identified cell lines with endogenous surface HLA-E expression ( It is known that IFN, secreted by immune cells reactive to tumors, increases expression of HLA-E, which, in turn, promotes resistance to NK cells via NKG2A ligation (23) . We determined whether improvements in tumor cell killing brought about by NKG2A downregulation with PEBL extended to tumor cells exposed to IFN. After 12 hours of exposure to IFN(300 ng/mL), EW8, PLC/PRF/5, and U937 overexpressed HLA-E (Fig. S10 ). These cells were consistently more susceptible to killing by NKG2A null NK cells than by control NK cells (P <0.01 for PLC/PRF/5, P <0.0001 for both EW8 and U937) (Fig. 6C) .
Because NK cells secrete IFN during activation (Fig. S6) , we postulated that exposure to the supernatant from co-cultures of NK cells and target cells would also induce NK cell resistance in tumor cells. To test this notion, we cultured NK cells with EW8 or U937 cells for 24 hours, collected and filtered the supernatant, and added it to fresh EW8 and U937. After 12 hours, we compared NK cells with and without NKG2A downregulation in 4-hour cytotoxicity assays. As shown in Fig. 6D , exposure to the NK conditioned medium induced considerable resistance to NKG2A + cells but NKG2A null cytotoxicity remained high (for EW8, P <0.0001 at 2:1 and 1:1, and P <0.01 at 1:2; for U937, P <0.0001 at 2:1, and P <0.01 at 1:1 and 1:2).
Previous studies have shown that AML cells from patients overexpress HLA-E after exposure to IFN, suggesting that this might favor the growth of NK-resistant leukemic cells (33) . We obtained 4 bone marrow specimens from patients with AML collected at diagnosis (n=3) or relapse (n=1) and containing over 90% AML blasts. We exposed the cells to IFN (300 ng/mL for 12 hours) and used them as targets of NKG2A+ NK cells which had been transduced with either anti-NKG2D PEBL or GFP alone. As shown in (Fig. 6F) . Thus, the PEBL strategy not only downregulated NKG2A expression in NKG2A-positive NK cells but also suppressed NKG2A expression after stimulation and IL-12 exposure. When the cytotoxicity of PEBL-transduced NK cells exposed to IL-12 was tested using GpHLA-E K562 cells, there was a clear improvement in cytotoxicity over that of control NK cells (P <0.0001 at all E:T ratios tested) (Fig. 6G) . Median survival for the two groups was 22 and 36 days from tumor infusion. By contrast, the same NK cells with downregulated NKG2A by PEBL induced profound responses, which resulted in long-term survival for most mice (median survival was not reached after >269 days follow-up; P <0.001 by log rank test compared to control NK cells). In a second model, we engrafted the osteosarcoma line U2OS expressing GpHLA-E and treated mice with two infusions of NK cells 3 and 10 days after tumor injection (Fig. S11) . Again, control NK cells only slightly delayed relapse (median survival, 25 and 32 days, respectively). Also in this model NKG2A null cells had a clearly superior anti-tumor activity than their NKG2A+ counterparts (median survival, not reached after 60 days follow-up; P <0.01). Of note, no evidence of xenoreactivity (weight loss, ruffled fur, abnormal posture, or decreased activity) was observed.
Anti
DISCUSSION
The unique capacity of NK cells to recognize and kill tumor cells (8,9) has been corroborated by reports of major clinical activity in some patients (6, 7) , suggesting that NK cell The importance of the CD94/NKG2A-HLA-E immune checkpoint in regulating NK cell activity against tumors has led to the ongoing clinical testing of an anti-NKG2A inhibitory antibody (39, 40) . We used the sequence of the heavy and light chain regions of an anti-NKG2D antibody as a basis to develop an anti-NKG2A scFv. We found that when the scFv was coupled to selected ER/Golgi retention domains, downregulation of NKG2A was rapid and nearly absolute. Importantly, NKG2A+ NK cells with NKG2A downregulation had more powerful cytotoxicity than those exposed to the anti-NKG2A antibody. This could be explained by the fact that CD94/NKG2A recycles between cell surface and cytoplasm independently from HLA-E Expression of PEBL in NK cells relied on a culture system that has already been translated into a GMP-grade protocol or infusion of autologous or allogeneic NK cells in patients with cancer (8) . Several approaches are being tested clinically to improve the anti-cancer potential of NK cell infusions, such as ex vivo expansion (8, 72, 73) , activation with cytokines (4,6), infusion of antibodies against inhibitory receptors (39, 40, 74) . Other approaches, such as CAR expression (47, 75) , expression of activating receptors (76) , and of membrane-bound cytokines (77) , suggest possibilities to further enhance NK cell potency that warrant clinical 17 exploration. The NKG2A null generated in this study can evade a central mechanism of tumor resistance to NK cells. Importantly, NKG2A is also expressed in a subset of activated CD3+ T lymphocytes and its ligation can inhibit their function (23, 78, 79) . In mice, loss of function of Qa1b (equivalent to HLA-E in humans) resulting from an in vivo CRISPR screening increased sensitivity of tumor cells to immune cells (80) . Correlative studies in ovarian and cervical carcinomas have shown a predominant infiltration of CD8+ lymphocytes expressing NKG2A (26, 81) , and recently published studies indicate that an anti-NKG2A antibody can augment T cell anti-tumor activity (41, 82) . Thus, the approach described here could potentially be extended to protocols of adoptive T cell therapy of cancer.
MATERIALS AND METHODS
Gene expression studies
RNAseqv2 expression data from 10,375 individual tumor annotated samples was downloaded from The Cancer Genome Atlas (TCGA) web portal ( https://gdc.cancer.gov).
Thirty three tumor types, as defined by TCGA codes, were included (Fig. 1) . Pairwise gene expression correlation values and associated p values were calculated in R. Gene expression box plots were generated using R graphics package GGPLOT2 (83) . Ordered column plots, scatter plots and linear regression lines were plotted in Microsoft Excel or GraphPad (San Diego, CA).
Analyses were also performed using TIMER (https://cistrome.shinyapps.io/timer/) (42) .
Cells
The human cell lines NK92, K562, SK-BR-3, PLC/PRF/5, U2OS, U937, were obtained from the American Type Culture Collection (ATCC; Rockville, MD). ES8 and EW8 were from 
NK cell expansion and NKG2A selection
To expand NK cells, peripheral blood mononucleated cells were co-cultured with the genetically modified K562-mb15-41BBL cell line, in SCGM medium (CellGenix, Freiburg, Germany) containing 10% FBS and 40 IU/mL of IL-2 (Proleukin, Novartis, Basel, Switzerland) (8, 47, 48, 51, 76, 77, 85) . After 5-7 days of culture, residual T cells were removed using Dynabeads CD3 (ThermoFisher). NK cells were labeled with allophycocyanin (APC)-conjugated anti-CD159a (NKG2A) antibody followed by anti-APC MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany); the LS-and LD-column (Miltenyi Biotec) were used to select or remove NKG2A+ cells, respectively. Selected NK cells were re-stimulated with K562-mb15-41BBL cells and 400 IU/mL IL-2. Recombinant human IL-12 (R&D; 20 ng/ml) was used in some experiments.
PEBL constructs
We designed a scFv containing the variable regions of the heavy and light chains of the murine anti-human NKG2A monoclonal antibody Z199 (17, 43) , and a 20 amino acid linker. To construct the anti-NKG2A PEBLs, the nucleotide sequence was joined to the CD8 signal peptide and sequences encoding ER/Golgi retention peptides (GGGGS)4AEKDEL (PEBL1), or CD8 hinge and transmembrane domain followed by LYKYKSRRSFIEEKKMP (PEBL2), LYKYKSRRSFIDEKKMP (PEBL3), or LYCNKYCKSRRSFIEEKKMP (PEBL4; Fig. 1a ).
Constructs were subcloned into the MSCV-derived retroviral vector containing IRES and GFP.
Preparation of retroviral supernatant and transduction were performed as previously described (85) . Briefly, MSCV retroviral vector-conditioned medium was added to polypropylene tubes coated with RetroNectin (Takara, Otsu, Japan); after centrifugation and removal of the supernatant, NKG2A selected and re-stimulated NK cells were added to the tubes and left at Cell marker and mRNA expression 20 Expression of PEBLs was detected using a biotin-conjugated goat anti-mouse F(ab')2 antibody (Jackson ImmunoResearch, West Grove, PA) followed by streptavidin conjugated to APC (Jackson ImmunoResearch). Other antibodies used to determine cell marker expression are listed in Table S3 . Intracellular staining for CD94 was performed after surface staining with anti-NKG2A and permeabilization with 8E, a reagent developed in our laboratory. Cell staining was analyzed using Accuri C6 or Fortessa flow cytometers (BD Bioscience), with Diva (BD Biosciences) or FlowJo software (FlowJo, Ashland, OR).
Whole transcriptome mRNA sequencing library preparation of NK cells with or without NKG2A downregulation was performed using TruSeq stranded mRNA library prep kit (Illumina, San Diego, CA) and sequenced on a NextSeq 500 platform with a read length of 2 x 151 bp. The reads were mapped to the human genome reference hg19 using STAR (86) . Reads aligned to each gene were counted using featureCounts (87) and the expression level was calculated as Fragments Per Kilobase of transcript per Million mapped reads (FPKM). The expression levels were log transformed, followed by batch effect correction using ComBat of sva package for downstream analysis (88) . Data available at geo@ncbi.nlm.nih.gov (Series No.
GSE127081).
Cytokine production, CD107a staining and cytotoxicity assays
To measure IFN production, NK cells were co-cultured at 37 Plates were then transferred into the IncuCyte Zoom System. On day 8, NK cells were added.
Images were captured with IncuCyte Zoom System and 10X objective lens at 6 hours intervals.
Tumor cell growth was quantified based on the fluorescence intensity of mCherry.
To interfere with NKG2A function, we used a purified non-conjugated anti-NKG2A antibody (Z199, Beckman Coulter); an isotype matched non-reactive immunoglobulin (R&D) was used as a control. In some experiments, we used as targets cell lines (K562, ES8, EW8, U2OS, and SK-BR-3) transduced with a construct encoding HLA-E with its signal peptide (MVDGTLLLLLSEALALTQTWA) replaced with the HLA-G signal peptide 
Statistics
For RNA sequencing analysis of NK cells, paired t-test was used to compare the expression level with statistical analysis performed using R. Controlling for false discovery rate was done using the 2-stage linear step-up procedure of Benjamini, Krieger and Yekutieli with a Q of 1% using GraphPad. No P values were marked as "discoveries". Comparisons of NK cell cytotoxicity were analysed using t-test; P <0.05 was considered significant. Mice survival was analyzed by log rank test.
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